Editas Medicine (EDIT)

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).

7 CRISPR Stocks for the Future of Medicine

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 15, 2021

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.

Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today

By William White, InvestorPlace Writer Dec 21, 2020

Editas Medicine (EDIT) stock is soaring higher on Monday with heavy trading despite a lack of recent news from the gene-editing company.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

By Alex Sirois Aug 13, 2020

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

7 Biotech Stocks to Buy and Hold in 2020

By Chris Lau, InvestorPlace Contributor Mar 16, 2020

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

The Top 3 Gene-Editing Stocks to Own in 2020

By Ian Cooper Mar 11, 2020

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

3 Biotech Stocks That Are Set for a Breakthrough

By Matt McCall, Editor, MoneyWire Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By Matt McCall, Editor, MoneyWire Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

54 Biggest Movers From Friday

From Benzinga Apr 19, 2021

Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share. General Finance...

Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks

From The Motley Fool Apr 16, 2021

Investors are trying to figure out which stocks have the best prospects.

Friday Sector Laggards: Biotechnology, Drugs

From Market News Video Apr 16, 2021

In trading on Friday, biotechnology shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Editas Medicine, down about 15.4% and shares of Veracyte down about 14.4% on the day.

EDIT May 28th Options Begin Trading

From Market News Video Apr 8, 2021

Investors in Editas Medicine Inc (EDIT) saw new options begin trading today, for the May 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new May 28th contracts and identified one put and one call contract of particular interest.

EDIT Makes Notable Cross Below Critical Moving Average

From Market News Video Mar 4, 2021

In trading on Thursday, shares of Editas Medicine Inc (EDIT) crossed below their 200 day moving average of $41.03, changing hands as low as $38.89 per share. Editas Medicine Inc shares are currently trading off about 9.2% on the day..

Why Editas Medicine Stock Is Getting Crushed Today

From The Motley Fool Apr 16, 2021

Investors are running for the hills following this analyst take on the biotech's prospects.

Editas Medicine (EDIT)

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

Louis Navellier's Top 6 Stocks for 2021

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Editas Medicine (EDIT)

Louis Navellier's Top 6 Stocks for 2021

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

EDIT Stock Predictions, Articles, and Editas Medicine News

Subscriber Sign in